The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release injectable suspension) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance ...
Long-acting risperidone is a suspension administered by intramuscular injection in the upper-outer gluteal area. It consists of risperidone impregnated in microspheres composed of a biodegradable, ...
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular). The Food and Drug Administration (FDA) has approved Rykindo ® ...
Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
Objective: To prospectively compare risperidone with conventional antipsychotic agents among schizophrenia patients treated under usual practice conditions. Design: One-year, multicentre, open-label, ...
Some patients have been sickened and at least one may have died when they were inadvertantly given the antipsychotic drug risperidone (Risperdal) instead of the Parkinson’s drug Requip (ropinirole) or ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced the positive outcome of an end-of-phase ...
Risperidone is an antipsychotic with known side effects that clinicians must balance against its benefits for a subset of autistic people. Although it can, for some autistic people, help reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback